As the Founder, President, Chief Executive Officer, and Chairman of Seattle Genetics, Inc. headquartered in Bothell, Washington, Clay Siegall is happy to have tackled his very big decision to form an innovative clinical-stage biotechnology company to develop monoclonal antibody-based therapies to advance the treatment of cancer and autoimmune diseases for blood-related cancers and solid tumors.
The company’s therapies are designed to meet unmet medical needs and improve important treatment outcomes for the affected patients. Its industry-leading antibody-drug conjugate (ADC) harnesses the antibodies’ ability as cell-killing agents to be delivered to infected cancer cells.
ADCETRIS® (brentuximab vedotin), which is the lead product collaborating with Takeda Pharmaceutical Company Limited, comprises the first in the class of ADCs that are commercially available in 65 countries to treat Hodgkin lymphoma (HL) as well as relapsed systemic anaplastic large cell lymphoma (sALCL). There are a number of products, clinical trials, and research projects that are being undertaken.
Clay Siegall, Ph.D., in 1998 co-founded Seattle Genetics and guided the capital-raising activities that secured over $675 million through private and public financing for the company’s initial public offering in 2001. His leadership has headed a diverse pipeline of antibody-based cancer therapies. That included ADCETRIS (brentuximab vedotin) which, in 2011, was granted approval by the U.S. Food and Drug Administration (FDA).
On Tuesday, November 8, 2016, Siegall presented at the Credit Suisse 25th Annual Healthcare Conference in Scottsdale, Arizona. The presentation was webcast live and is available for replay from the website at www.seattlegenetics.com.
Before Seattle Genetics, Dr. Siegall was very active from 1991 to 1997 with the Bristol-Myers Squibb Pharmaceutical Research Institute. Prior to that, from 1988 to 1991, he was with the National Cancer Institute, National Institutes of Health. He currently also serves on the Board of Directors of the private biotechnology company Alder BioPharmaceuticals, gives frequent professional talks, is an author of over 70 publications, and is the holder of 15 patents.